Highlights

  • Institutional placement of A$20 million significantly oversubscribed, alongside A$3.1 million from existing shareholders exercising options
  • Share Purchase Plan (SPP) of up to A$2 million to allow retail investors to participate
  • Funds will support manufacturing, sales, marketing, and broader commercialisation of FebriDx® in the United States

Lumos Diagnostics Holdings Limited (ASX:LDX) successfully raised A$20 million through an institutional placement, which was substantially oversubscribed, along with an additional A$3.1 million from existing shareholders exercising options. The company also announced a Share Purchase Plan (SPP) of up to A$2 million for eligible shareholders in Australia and New Zealand. These funds will be directed towards expanding manufacturing capacity, building a dedicated US sales and marketing team, supporting the commercial launch of FebriDx® in outpatient settings, and exploring new proprietary products. The US FDA’s CLIA waiver for FebriDx® opens a large market opportunity, allowing rapid, point-of-care testing for acute respiratory infections. With a strengthened balance sheet, Lumos is positioned to execute its growth strategy and scale operations efficiently, while maintaining flexibility for future initiatives.

Placement and Share Purchase Plan Details

The institutional placement involved issuing up to 88.9 million new shares at A$0.225 per share, with one free-attaching option for every two shares subscribed, exercisable at A$0.34 until 31 December 2027. The placement price represented a 15% discount to the last closing price. The SPP will offer the same terms to eligible retail shareholders, allowing participation in the company’s growth at the same price, with free-attaching options issued on the same basis. Funds raised through both initiatives will strengthen the company’s balance sheet and provide capital to scale manufacturing, marketing, and US commercial operations.

Use of Proceeds and Strategic Outlook

Proceeds from the placement and SPP will be allocated to expanding FebriDx® manufacturing capacity in Carlsbad, California, establishing a dedicated sales, marketing, and medical implementation team for the US commercial launch, and assessing additional proprietary products. Funds will also repay amounts drawn under existing loans, cover placement and SPP costs, and support general working capital. The CLIA waiver positions Lumos to address a large outpatient diagnostics market, enabling rapid, point-of-care testing for acute respiratory infections. Management views the successful capital raising as a critical milestone for scaling operations, driving commercial momentum, and delivering sustainable growth.